IMV

Share on: 
Website: IMV
Description: 

IMV is a clinical-stage biopharmaceutical company leveraging our proprietary drug delivery platform, DPX, to generate cancer-targeted T cells. Our lead candidate, DPX-Survivac, is a first of a novel class of immunotherapy and targets survivin, an antigen present in more than 20 solid and hematological tumor types.

COVID-19: (03/30/20) Creating a vaccine candidate for COVID-19 based off DPX-Survivac, a T-cell activating immunotherapy antigen vaccine

Career Page(s): 
Location(s): 
Québec QC
Canada